Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab

Bidirectional Association between Psoriasis and Atopic Dermatitis: A Nationwide Population-Based Cohort Study

“…Similarly, there have been some reports that patients with psoriasis developed AD after the treatment of biologics [43, 44]. Some authors proposed that inhibition of the Th2 pathway may result in a shift toward the Th1 inflammatory pathway and vice versa [41, 44]. In the current study, the sensitivity analysis excluding psoriasis patients with prior use of biologics showed similar results in the association between psoriasis and risk of AD.…”

De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort

“…L. Jaulent, 1 D. Staumont-Sall e, 2 M. Tauber, 3 C. Paul, 3 H. Aubert, 4 A. Marchetti, 5 B. Sassolas, 6 A. Valois, 7 J.-F. Nicolas, 1,8 A. Nosbaum, 1,8,* for GREAT Research Group 1 Allergy and Clinical Immunology Department, Univ Lyon, Lyon Sud…”

Increased expression of interleukin‐23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment

“…Dupilumab is a human monoclonal antibody directed against the α subunit of the IL‐4 receptor, approved for the treatment of moderate‐to‐severe AD. Some cases of psoriasiform reaction during dupilumab therapy (D‐PsoR) have been described, but its mechanism remains unknown 2–6 . The study aim was to investigate the Th17/23 axis involvement in patients with AD with D‐PsoR, compared with patients with AD and patients with Pso.…”